No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track

Launched by KAFRELSHEIKH UNIVERSITY · May 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called tirofiban, which is used to help improve blood flow in patients who have suffered a heart attack known as STEMI (ST-segment elevation myocardial infarction). The researchers want to see how effective tirofiban is in preventing a condition called "no-reflow," where blood vessels remain blocked even after treatment. This study is currently looking for participants aged 18 and older who have experienced a STEMI and have typical symptoms like chest pain and changes seen on an electrocardiogram (a test that checks heart activity).

If you or a loved one is considering joining this trial, there are some important things to know. Eligible participants must not have received certain treatments, like clot-dissolving drugs, in the past 24 hours, and should not have specific health issues such as severe liver disease or certain types of cancer. Those who join the trial can expect to receive close monitoring and care from medical professionals throughout the process. This study aims to provide valuable information that could help improve treatments for heart attack patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years old.
• • Both sexes.
• • Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain \>30 minutes with ST-segment elevation of \>1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block.
• Exclusion Criteria:
• • Treatment with thrombolytic drugs in the previous 24 hours.
• • Known malignancy.
• • Thrombocytopenia.
• • End-stage liver disease.
• • Cardiogenic shock.
• • Renal failure with glomerular filtration\<30 ml/min.
• • Contraindication for the use of tirofiban.